Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + capecitabine
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
**Trastuzumab deruxtecan + capecitabine** is a combination of two anti-cancer drugs used in investigational regimens for advanced or metastatic breast cancer. **Trastuzumab deruxtecan** is an antibody-drug conjugate (ADC), composed of the anti-HER2 monoclonal antibody trastuzumab covalently linked to the topoisomerase I inhibitor deruxtecan, which targets HER2 receptors on tumor cells to deliver a cytotoxic agent directly and induce cell death by DNA damage. **Capecitabine** is an orally administered small-molecule prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite that inhibits DNA synthesis by blocking thymidylate synthase. This combination is under investigation for hormone receptor–positive or negative, HER2-low or HER2-positive metastatic breast cancer.
- Brand names
- Enhertu + Xeloda
- Other names
- T-DXd + capecitabine
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab deruxtecan + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + capecitabine.